Krystal Biotech’s (KRYS) “Buy” Rating Reaffirmed at HC Wainwright

Krystal Biotech (NASDAQ:KRYS)‘s stock had its “buy” rating reaffirmed by investment analysts at HC Wainwright in a research report issued to clients and investors on Friday,Benzinga reports. They currently have a $221.00 price target on the stock. HC Wainwright’s price target would suggest a potential upside of 26.42% from the company’s current price.

Several other research analysts have also recently weighed in on KRYS. Chardan Capital increased their price target on shares of Krystal Biotech from $212.00 to $218.00 and gave the company a “buy” rating in a report on Thursday, February 20th. Cantor Fitzgerald reissued an “overweight” rating and issued a $215.00 price objective on shares of Krystal Biotech in a research note on Thursday, February 20th. Finally, Citigroup lifted their price objective on shares of Krystal Biotech from $206.00 to $215.00 and gave the company a “neutral” rating in a research note on Thursday, February 20th. One equities research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $215.83.

Krystal Biotech Price Performance

NASDAQ KRYS opened at $174.82 on Friday. The firm has a market cap of $5.04 billion, a P/E ratio of 58.52 and a beta of 0.84. The stock’s 50-day moving average is $159.13 and its two-hundred day moving average is $175.30. Krystal Biotech has a fifty-two week low of $141.72 and a fifty-two week high of $219.34.

Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings data on Monday, February 24th. The company reported $1.52 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.29 by $0.23. Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. The firm had revenue of $91.10 million for the quarter, compared to analysts’ expectations of $91.35 million. During the same period last year, the firm earned $0.30 earnings per share. The business’s revenue for the quarter was up 116.4% on a year-over-year basis. On average, equities analysts expect that Krystal Biotech will post 6.14 EPS for the current year.

Insiders Place Their Bets

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction on Friday, December 13th. The stock was sold at an average price of $164.78, for a total transaction of $4,119,500.00. Following the transaction, the insider now directly owns 1,475,882 shares in the company, valued at approximately $243,195,835.96. This trade represents a 1.67 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 14.10% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the company. Wilmington Savings Fund Society FSB bought a new position in shares of Krystal Biotech during the 3rd quarter worth approximately $40,000. GF Fund Management CO. LTD. purchased a new stake in shares of Krystal Biotech during the 4th quarter valued at $95,000. Huntington National Bank raised its stake in shares of Krystal Biotech by 97.6% during the 3rd quarter. Huntington National Bank now owns 573 shares of the company’s stock worth $104,000 after purchasing an additional 283 shares during the period. Covestor Ltd boosted its holdings in shares of Krystal Biotech by 972.7% in the 4th quarter. Covestor Ltd now owns 708 shares of the company’s stock worth $111,000 after buying an additional 642 shares during the last quarter. Finally, KBC Group NV grew its position in Krystal Biotech by 25.9% during the third quarter. KBC Group NV now owns 642 shares of the company’s stock valued at $117,000 after buying an additional 132 shares during the period. 86.29% of the stock is owned by institutional investors.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).